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1. Abstract 
The aim of this study was to investigate magnetic resonance images (MR) from 
patients with schizophrenia and healthy control subjects for difference in brain 
morphology with focus on subcortical brain volumes. 
Method: The study compared fourteen subcortical brain structure volumes of 96 
patients diagnosed with schizophrenia (n=81) or schizoaffective disorder (n=15) with 
106 healthy control subjects. Volume measures were obtained using voxel-based 
morphometry (FreeSurfer software suite) of T1-weighted MR images. 
Results: When adjusting for intracranial volume, age and gender, the hippocampus 
volume was smaller both on the right and left side in the patient group (p<.001) as 
compared with healthy controls. Pallidum was found to have an increased volume 
bilaterally in the patients (p<.001), and volume was positively related with disease 
duration and inversely with age at onset. Caudate and amygdala in the right 
hemisphere was larger (p<.01) and showed trend effects for being larger also in the 
left hemisphere.  There was a trend for a larger right accumbens in the patients.  
First generation neuroleptic medication affected basal ganglia volumes differently 
than second generation neuroleptics with stronger effects on putamen but also on 
pallidum volume increase. 
Conclusions: Schizophrenia has brain morphological correlates, and this study 
confirms that hippocampus is reduced in patients with schizophrenia. This study also 
presents an interesting subcortical brain region volume difference regarding 
medication.  
Keywords 
Schizophrenia, magnetic resonance imaging, voxel-based morphometry, subcortical 
brain structures, antipsychotic medication.  
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2. Background 
2.1 Schizophrenia 
Schizophrenia is a chronic disease affecting about 1 % of the population world-wide 
(1). The severity may be illustrated by a suicide rate of 10% (1), about 75% of the 
patients have relapses and continued disability and one out of three fails to respond to 
standard treatment (2). 
2.1.1 Symptoms 
The disease is characterized by fundamental and characteristic alterations of thinking 
and perception; inappropriate or blunted affects, thought echo, which may have the 
character of thought insertion or withdrawal, or thought broadcasting, hallucinatory 
voices commenting or discussing the patient in the third person (3). 
The symptoms are often categorized in clusters; positive symptoms, including 
hallucinations, delusions, thought disorder, and paranoia; cognitive dysfunction, 
especially in attention, working memory, and executive function; negative symptoms 
with anhedonia, social withdrawal and thought poverty (4). The symptom clusters do 
not exclude each other, but they are often present in different degrees across patients. 
2.1.2 Etiology and Epidemiology 
The etiology of schizophrenia remains unclear and is considered to be multifactorial. 
Heritability is estimated to up to 85% (5,6) and supported by increased risk in 
individuals with a schizophrenic sibling; 8-10%, and a concordance rate of 40-50% 
among monozygotic twins (4). 
This risk pattern is not consistent with heritability as the single cause for 
schizophrenia (1). Prenatal maternal illnesses during the second trimester and 
perinatal birth complications have also been found to be predisposing risk factors (4). 
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Other risk factors include substance use, and traumatic life events (2). Men are more 
frequently and more severely affected than women (1), with a risk ratio men:women 
found to be 1.4 (7). 
Being born in cities, having moved to a city, social migration and migration in 
general, as well as being born in winter or spring, have also been found to have a 
positive correlation with the incidence of schizophrenia (7-9). Paternal age is risk 
factor of intermediate magnitude (10). It should be noted that such findings do not 
imply causality, but might be due to a hitherto unknown confounding factor. 
2.1.3 Treatment 
Antipsychotic pharmaceutical therapy, family interventions, and psychoeducational 
interventions have shown to be effective in ameliorating symptoms of schizophrenia 
(2). First-generation antipsychotic agents (FGA), e.g. haloperidol and 
chlorpromazine, are effective in the treatment of positive psychotic symptoms, but 
associated with motor side-effects (11,12). 
The second-generation antipsychotics (SGA), e.g. risperidone, olanzapine, 
quetiapine, ziprasidone, and aripiprazole are effective and generally better tolerated 
but, are associated with metabolic side-effects, including weight-gain and increased 
triglycerides and cholesterol (12,13). Pharmacological treatment has shown good 
effect on positive symptoms, but no pharmaceutical treatment has been proved to be 
effective on negative symptoms (11-13). 
While FGAs generally act as dopamine D2-receptor antagonists (13), many SGAs 
have a high serotonin 5-HT2A-receptor/D2-receptor affinity ratio (14). This may be 
explanatory to the differences in both effects and side-effects seen between the two 
groups of medication.  
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2.2 Brain structure in schizophrenia 
2.2.1  Findings from neuroimaging studies 
Reduced total brain volume 
The advance of in vivo magnetic resonance imaging (MRI) techniques has allowed 
for an increasingly accurate investigation of brain structures. Although not always 
reproducible (15), total brain volume is found to be reduced in patients with 
schizophrenia compared to healthy controls by approximately 2 % (16,17). 
Ventricular enlargement 
The most prevalent findings include ventricular enlargement (18,19) and regional 
volume reduction in the superior temporal gyrus, thalamus, hippocampus, and frontal 
lobe (18,19) . Increased ventricular volume in schizophrenia was shown in early 
computer tomography (CT) studies (20), and is a consistent finding in schizophrenia 
(16). A study by Gaser et al. supports the hypothesis that ventricular enlargement is 
due to focal volume decreases, especially in the thalamus, putamen, and superior 
temporal gyrus (21). 
Reduced fronto-temporal cortical thickness 
Reduced cortical thickness has been found in patients diagnosed with schizophrenia 
in widespread areas in prefrontal and temporal brain regions, bilaterally (22,23). 
Reductions in prefrontal cortical white matter volume have been associated with 
negative symptoms (24). 
Impairment of brain circuitry 
Affective and cognitive components of symptom spectrum associated with 
schizophrenia, such as empathy and executive function, represent higher level brain 
processes (25). Morphological brain correlates of schizophrenia are thought to 
implicate a network of frontal, temporal, limbic, striatal, and thalamic regions 
showing reduced grey matter in patients (26). 
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2.2.2 Effects of treatment and duration 
Medication can affect brain region volumes. In a recent meta-analysis of bipolar 
disorder, lithium use was associated with increased total gray matter volume (27), for 
example. Antipsychotic medication has been found to increase basal ganglia volume 
(28), although this was in a small group of patients (n=29) and healthy controls 
(n=10). Other studies indicate that this effect is restricted to haloperidol, and not 
found in subjects who have used second generation antipsychotics (29). In line with 
the hypothesis that volume change is dependent on the antipsychotic drug 
administered, a recent study not discriminating FGA and SGA medication found no 
dosage effect on any subcortical volumes (30). Findings from the same study indicate 
a correlation between greater volume loss and poor clinical outcome (30). 
Age is another factor that is found to strongly correlate with total grey matter volume, 
as well as specific brain regions (31). The regression slope was also found to be 
steeper in patients compared to controls, suggesting a progressive loss of grey matter 
(31,32). 
2.2.3 Brain imaging methods 
Voxel-based morphometry (VBM) 
One voxel represents the smallest three-dimensional volume element of an MR-
image, thus the size of a voxel depends on the resolution of the MR image, as is the 
case with a pixel of a two-dimensional image. VBM is an image analysis or image 
post processing method that calculates the probability of the presence of gray or 
white matter voxel by voxel (32), also described as the density of gray and white 
brain matter(33). The method is automated and may calculate brain region volumes 
of the whole brain(33).  
Region of interest (ROI) studies 
This method is based on an a priori hypothesis and manual outlining to obtain volume 
measurement (34). VBM-based methods are automated or semi-automated and allows 
for measuring several structures simultaneously in the brain, while region-of-interest-
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based studies typically measure one structure at a time usually by manual delination 
which is time-consuming and disadvantageous in the case of large subjects samples. 
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3. Aim 
The aim of this study was to study subcortical volumes in patients diagnosed with 
schizophrenia compared to healthy controls, and to investigate correlations between 
volume and medication, duration of illness and age at onset. 
3.1 Hypothesis 
The main hypothesis of this study was; subcortical brain volumes in patients 
diagnosed with schizophrenia differ from healthy controls. Two subsequent 
hypothesises were formulated; hippocampus volume is decreased, and; basal ganglia 
volume is correlated to the antipsychotic medication administered. 
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4. Methods 
4.1 Material 
The data in this paper has been obtained as a part of the Human Brain Informatics 
(HUBIN) project. The project was planned and performed at the Karolinska Institutet 
and Hospital in Stockholm. All subjects have given their written consent to 
participate in accordance with the Declaration of Helsinki, the project was approved 
by the regional and local research ethics committees of the Karolinska Institutet. 
4.1.1 Subject description 
Patients were included from four psychiatric clinics specialized in the treatment of 
psychosis in Stockholm County, Sweden, between 1998 and 2003. They were asked 
to participate in a clinical interview, deliver blood-samples for biochemical and 
genetic investigation, to undergo an MR investigation of the brain structure, and 
permission was given to access their medical record. The clinical interview included 
the Structured Clinical Interview for the DSM-IIIR (SCID-I) (36) and patients were 
classified according to DSM-IIIR or DSM-IV diagnostic criteria. Healthy control 
subjects were recruited from population registers, and among hospital staff and 
students at the participating centres. 
A subpopulation of these patients has been described earlier (37), focusing on 
caudatus, putamen and nucleus accumbens grey and white matter volumes from 
manual delineation. 
The dataset consisted of 111 patients divided into 6 diagnosis categories and one 
healthy control group (n=106).Seven patients not categorized by diagnosis were 
excluded. Eight patients who did not fill the diagnostic criteria (including one subject 
with confirmed hepatitis C infection) were excluded. 
The main calculations will be made merging the schizophrenia (n=81) group and the 
schizoaffective disorder (n=15) groups, here referred to as the Patient group (n=96). 
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Age at onset was defined as onset of psychotic symptoms according to any available 
source. Duration of illness was defined as the difference in years between age at onset 
and age at investigation (22).  
Local guidelines at Karolinska Institutet made up the basis for calculation of 
haloperidol equivalent dosage, based on an interview and medical records. 
Antipsychotic medication was classified as first-generation,  including haloperidol, 
perfenazine, zuclopenthixole, and fluanxol (n=41) or second-generation, including 
clozapine, olanzapine, and risperidone (n=44). Three patients received both FGA and 
SGA medication and 8 patients received no medication. Further description is 
featured in table 1. 
4.2 MRI acquisition and post-processing 
The same 1.5 Tesla General Electronics Signa scanner system at the MR Research 
Centre at the Karolinska Institutet was used for examination of all subjects. A three-
dimensional spoiled gradient recalled pulse sequence was used for T1-weighted 
images with the following parameters: 1.5 mm coronal slices, no gap, 35° flip angle, 
repetition time 24 ms, echo time 6.0 ms, number of excitations 2, field of view 24 cm, 
acquisition matrix 256 x 192. Data from T1-weighted images were used for image 
post processing. 
4.2.1 Image processing 
The MRI data represents a three-dimensional matrix of volumetric units, voxels, with 
registered signal intensity from 0 to 1. The value tends to be closer to either one of 
these extremes, thus not normally distributed. The MRI smoothing process 
contributes to normalizing the data, as well as allowing segmentation at higher 
resolution than the original MRI data, by averaging nearby located voxels (33). 
4.2.2 Freesurfer segmentation 
The FreeSurfer segmentation procedure automatically identifies volumes of 
subcortical structures (32,38). The algorithm labels each voxel as one of 40 brain 
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structures (38). A reliability study has also been conducted to validate the software 
used in this study, where five experts independently labelled subcortical regions 
manually. The calculated volumes were then compared to the volumes calculated on 
the basis of automatically labelled volumes, resulting in statistically indistinguishable 
results (32). 
4.3 Statistical analysis 
Software 
Automatic subcortical labelling and volume measurements were performed with 
FreeSurfer version 2.2.3 running on an Apache Linux system. The FreeSurfer image 
analysis suite is freely available (39). SPSS version 16 for Windows was used for 
statistical analyzes. Microsoft Excel was used for data analysis and graphical 
presentation. 
The studied brain volumes 
The FreeSurfer software calculates a wide array of data from the entire brain, 
including 40 defined subcortical volumes. The automatically delineated volumes 
studied include thalamus, caudate, putamen, pallidum, hippocampus, amygdala and 
accumbens.  All subcortical volumes are presented as absolute volumes (mm
3
). This 
is a more direct approach than to study volumes relative to total intracranial volume, 
although often performed (16,17,40,41). To correct for individual variance in head 
size, intracranial volume (ICV) was added as a covariate in the statistical analyses. 
Statistical methods applied 
The normality of subcortical volume distributions within the patient and control 
groups were investigated by visual inspection of residuals of all groups studied.  
Student’s T-test was used to investigate differences in descriptive variables across all 
groups studied. Except for administered haloperidol equivalents, no difference was 
found. Patients receiving SGA had a higher daily haloperidol equivalent dosage 
compared to patients receiving FGA, 5.6 and 2.7 mgeqv/daily, resceptively. 
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Mean volumes were compared across subject groups, including ICV as a covariate in 
an analysis of covariance (ANCOVA). To validate the findings, age and gender were 
then added as covariates as well. Comparing across subgroups defined by the 
medication they used, required three statistical tests. A Bonferroni test with alpha 
level adjusted to 0.016 was used to correct for multiple comparisons. 
To investigate the effect of medication, age at onset of illness and duration of illness, 
partial correlation coefficients were computed when controlling for age, gender and 
ICV. Medication was investigated in terms of haloperidol equivalents and a 
dichotomous classification as FGA or SGA. 
As a basis for performing these tests, normality of distribution, correlations amongst 
covariates, linearity, and homogeneity were investigated to make sure the data have 
the distribution required for the tests to be valid. 
As mentioned above, gender was added as a covariate in an ANCOVA model, thus 
operating with dichotomous data in a model which requires normally distributed data. 
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5. Results 
No significant differences in age or gender distribution were found between the 
control and patient groups. As shown in Table 2, the volume of the hippocampus on 
both sides was found to be highly significantly smaller in the patient group. Pallidum 
on both sides were found to be larger in the patient group. As noted in Figure 5, all p-
values were <.001, also when adjusting for age and gender. In this study, no 
significant difference in total intracranial volume was found. 
Right caudate and right amygdala were significantly larger and smaller volumes, 
respectively, in the patient group compared to healthy controls, F=7.2, p=.008 and 
F=7.5, p=.007 respectively. 
Trends 
There were trends for caudate and amygdala on the left side (F=5, p=.03 for both 
structures). Table 2 and figure 5 clearly shows that the differences are in the same 
direction bilaterally, supporting the consistency of this finding within this material. 
Effects of disease duration and medication at MRI 
A positive correlation between volume of pallidum and duration of illness and a 
negative correlation with age at onset, controlling for age, gender and ICV, was found 
(correlation coefficient 0.3, p<.01 for both tests). Details are presented in Table 3. 
No significant correlation between the subcortical volumes and administered 
haloperidol dosage at time of MRI was found in the patient group.  
FGA vs SGA medication 
A subgroup (n=85) within the patient group receiving either FGA (n=41) or SGA 
(n=44) medication was studied, thereby excluding patients receiving both and no 
medication. Comparisons were done on volumes adjusted for age, gender and ICV. 
Putamen volume in patients receiving FGA was larger as compared to both SGA and 
healthy controls. Caudate volume was larger in the FGA group compared to healthy 
controls, no significant difference was found between FGA and SGA groups. 
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Pallidum volume was larger in the FGA group compared to healthy controls 
bilaterally. Left pallidum was larger in SGA compared to healthy controls, whereas 
right pallidum in SGA was smaller than FGA. Hippocampus volume in both FGA 
and SGA groups were smaller than in healthy controls. Patients receiving first-
generation antipsychotic (FGA) medication were found to have a larger pallidum 
volume compared to patients receiving second-generation antipsychotic (SGA). 
All results are presented in table 4 and figure 7. 
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6. Discussion 
The hippocampus volume was significantly smaller in patients compared to healthy 
controls. The absence of difference in patients receiving FGA or SGA suggests this 
effect is due to the disease, rather than medication.  
Putamen volume bilaterally and the right pallidum volume were larger in patients 
receiving FGA compared to both SGA and healthy control groups. As no significant 
difference between patients receiving SGA and healthy control subjects was found, 
this suggests that the volume increase is due to the FGA medication. Left, but not 
right, pallidum was found to be significantly larger in patients receiving SGA 
compared to healthy controls as well, making it less likely that pallidum volume 
difference is a medication effect. 
The main hypothesis that subcortical brain volumes in patients diagnosed with 
schizophrenia differ from healthy controls was supported by the findings of this 
study. Findings from both the correlation analysis (Table3) and group-wise 
comparison by medication (Table 4) support the hypothesis that basal ganglia volume 
is correlated to the class of antipsychotic medication administered. No dosage-effect 
of medication on subcortical volumes was found in this study but measures were only 
obtained from one occasion (at MRI examination). 
Intracranial volume 
This material showed no significant difference in ICV between the two groups. This 
is in line with the more recent inconsistency of this finding (15). 
Subcortical volume differences 
In this study, we found reduced volumes of left and right hippocampus in the patients 
as compared to healthy subjects. Reduced hippocampal volume in patients diagnosed 
with schizophrenia has also been found previously (16). This finding is considered to 
be a consistent finding in schizophrenia (19).  
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Previous studies have found an increase in caudate, putamen and pallidum volumes in 
chronic schizophrenic patients (42), concordant with the findings of this study. 
Medication dosage 
Medication effects, associated with brain region volume enlargement (43), may have 
been a contributing factor to the previously reported larger pallidum volume in 
patients (44). The group difference found in this material, with larger putamen and 
right pallidum volumes in patients receiving FGAs compared to SGA, suggests that 
this may partly be due to the medication. As this is a cross-sectional study, 
conclusions cannot be drawn, but the findings do point out a potential direction for 
further investigation. This hypothesis could be tested in a follow-up study of this 
cohort. 
The calculation of haloperidol equivalent dosage is not at all straight-forward for 
antipsychotic drugs, and may be contributing to the difference in administered 
haloperidol equivalents found when comparing FGA and SGA. The pharmacological 
differences between FGA and SGA, as well as different molecular targets of action 
within the groups, complicate the matter. These problems of the calculation of 
haloperidol equivalent dosage suggest further studies to focus on individual 
antipsychotic drugs. Such a circumvention of this problem may require larger sample 
sizes to achieve adequate group sizes as the number of administered drugs increases.  
This data do not provide retrospective data on medication dosage. Dosage is tittered 
individually by symptom relief; a high dosage could be due to severity of symptoms 
as well as individual variations in pharmacokinetics, distribution and metabolism. As 
a result, this null finding does not imply that medication dosage is without effect of 
brain region volumes. 
FGA and SGAs 
The mechanism of antipsychotic drugs on brain volume remains uncertain. One 
hypothesis to explain the volumetric differences in the basal ganglia is that chronic 
D2-receptor antagonist influence leads to a receptor proliferation, which in turn leads 
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to increased metabolism, blood flow and size (45). SGA, having different receptor 
affinity, have been found to ameliorate this effect (45). 
With the exception of hippocampus and left pallidum, FGA had larger and SGA had 
smaller subcortical brain region volumes compared to healthy controls. This is in line 
with the trends of a recent review by Scherk and Falkai (45).  
Emerging evidence support a substantial diversity of antipsychotic drugs, also within 
the groups of  FGA and SGA (46). As the choice and combinations of drugs vary in 
clinical practise, an observational setting as this study requires some level of 
grouping in order to achieve an adequate power of the statistical analysis. Hence, the 
traditional classification of drugs as either FGA or SGA was chosen. 
The strengths of this study include a fairly large sample size and reproduction of 
previous findings.  
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Table 1 Descriptive variables 
 Patients (n=96)   Control  (n=106) 
 Mean Std. Dev. Range  Mean Std. Dev. Range 
Age 42.1 7.31 (25 - 57)  41.5 9.01 (19 - 56) 
Gender [male-female] [70 - 26]    [72 - 34]   
Age at onset, years
a
 24.6 5.89 (14 - 45)     
Duration, years
a
 17.3 8.62 (0.4 - 41.1)     
Medication Dosage
b
 3.97 3.28 (0 - 16)     
ICV
c
 1735 286 (1301 - 2420)  1722 300 (1275 - 2599) 
Antipsychotic medication (N)       
None 8       
First-generation 41       
Second-generation 44       
Both 3       
a. Data available for 94 patients 
b. Dosage converted to Haloperidol-equivalents, mg/day 
c. Volume 10
3
 mm
3
 
 
Table 2 Differences in subcortical volume measures between patients 
(n=96) and controls (n=106), adjusted for ICV, age and gender.  
 Patients  Controls  
Adjusted for  
age, gender and ICV 
 Mean
a
 Std. Error  Mean
a
 Std. Error  F p Eta sq
b
 
Left thalamus 7589.8 86.85  7687.5 82.65  1.75 0.187 0.01 
Right thalamus 7849.3 87.89  7797.8 83.64  0.02 0.877 0.00 
Left caudate 3821.6 49.40  3669.7 47.01  5.05 0.026 0.02 
Right caudate 3847.6 49.02  3667.7 46.65  7.18 0.008 0.04 
Left putamen 5593.4 62.50  5420.3 59.48  4.08 0.045 0.02 
Right putamen 5548.4 64.15  5341.2 61.05  5.69 0.018 0.03 
Left pallidum 2025.2 25.50  1865.2 24.26  24.92 < 0.001 0.11 
Right pallidum 1945.4 26.20  1811.4 24.93  15.44 < 0.001 0.07 
Left hippocampus 4126.9 45.29  4354.5 43.1  17.58 < 0.001 0.08 
Right hippocampus 4336.9 43.48  4536.5 41.38  14.77 < 0.001 0.07 
Left amygdala 1709.7 23.03  1760.8 21.92  5.02 0.026 0.02 
Right amygdala 1677.9 21.08  1738.9 20.06  7.51 0.007 0.04 
Left accumbens 547.7 9.93  556.6 9.45  0.63 0.428 0.00 
Right accumbens 558.4 9.42  585.1 8.96  5.30 0.022 0.03 
a. Raw volume mm
3
 
b. Partial eta squared 
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Table 3 Correlations between subcortical volumes and medication dosage, 
disease duration and age at onset at MRI in the patient group, adjusted for 
age, gender and ICV 
  Dosage
a
 (df=91)   Duration (df=89)   Age at onset (df=89) 
  corr
c
 p   corr
c
 p   corr
c
 p 
Left thalamus -0.051 0.625  0.175 0.097  -0.146 0.167 
Right thalamus -0.091 0.387  0.202 0.055  -0.185 0.080 
Left caudate -0.089 0.396  0.182 0.084  -0.162 0.124 
Right caudate -0.093 0.378  0.197 0.061  -0.180 0.088 
Left putamen -0.069 0.513  0.158 0.134  -0.145 0.171 
Right putamen -0.107 0.308  0.166 0.116  -0.162 0.126 
Left pallidum -0.054 0.609  0.336 0.001  -0.308 0.003 
Right pallidum -0.040 0.701  0.343 0.001  -0.318 0.002 
Left hippocampus -0.123 0.239  0.127 0.229  -0.143 0.178 
Right hippocampus -0.080 0.449  0.049 0.643  -0.070 0.510 
Left amygdala -0.075 0.472  -0.019 0.862  0.002 0.984 
Right amygdala -0.063 0.548  0.056 0.600  -0.051 0.633 
Left accumbens -0.197 0.058  0.109 0.306  -0.090 0.394 
Right accumbens -0.150 0.153   0.070 0.507   -0.077 0.471 
a. Neuroleptika-equivavelents, Haloperidol mg/day 
b. Antipsychotic medication, FGA and SGA coded as 1 and 2, respectively 
c. Correlation coefficient 
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Table 4 Comparison of subcortical volumes between a subgroup of patients 
(n=85) who received either FGA or SGA medication and healthy controls, 
calculated with ICV, age, and gender as covariates 
 FGA (n=41)
a
  SGA (n=44)
 a
  CTR (n=106)
 a
  P
b
 
  Mean Std. Error   Mean Std. Error   Mean Std. Error 
 FGA vs. 
SGA 
FGA vs. 
CTRc 
SGA vs. 
CTRc 
Left thalamus 7697 872.0  7556 806.4  7688 879.4  0.345 0.841 0.177 
Right thalamus 7983 823.1  7776 845.6  7798 897.5  0.213 0.274 0.700 
Left caudate 3904 481.3  3749 430.5  3670 514.4  0.120 0.008 0.398 
Right caudate 3956 461.9  3755 451.0  3668 500.4  0.045 0.001 0.333 
Left putamen 5783 537.4  5470 664.8  5420 587.4  0.008 >0.001 0.706 
Right putamen 5736 588.1  5404 676.9  5341 597.8  0.006 >0.001 0.618 
Left pallidum 2094 257.1  1981 226.6  1865 245.4  0.016 >0.001 0.004 
Right pallidum 2020 252.5  1890 248.2  1811 258.9  0.010 >0.001 0.070 
Left hippocampus 4189 575.2  4043 354.5  4355 398.2  0.119 0.014 >0.001 
Right hippocampus 4366 481.6  4272 399.7  4537 418.7  0.340 0.011 >0.001 
Left amygdala 1755 229.2  1663 200.7  1761 234.6  0.067 0.553 0.005 
Right amygdala 1704 232.8  1646 201.4  1739 203.6  0.245 0.154 0.004 
Left accumbens 566 83.5  533 109.8  557 93.1  0.122 0.662 0.153 
Right accumbens 579 83.3  541 91.3  585 90.2  0.036 0.639 0.003 
a. Raw mean volumes (mm
3
) 
b. Based on estimated marginal means controlling for ICV, age and gender 
P-values less than the Bonferroni adjusted alpha level (0.016) are in bold 
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9.2 Figures 
 
Figure 5 Significant volume differences 
Marginal means, adjusted for ICV, age and gender (95% CI) 
 
Volumes of subcortical brain regions (mm
3
) 
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Figure 6 Estimated marginal mean difference, patients - controls 
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Legend: *: p<0,05, **: p<0,001, ¤: F>10, ¤¤: F>20 
Crude difference of raw volumes (mm
3
). F and p are calculated based on estimated 
marginal means adjusting for age, gender and ICV.  
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Figure 7 Summary of significant differences; FGA vs. SGA vs. CTR, 
extracted from table 4 
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Comparison of raw volumes (mm3), p-values based on estimated means  
adjusted for ICV, age and gender. Bonferroni adjusted alpha level 0.016. 
 
